Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Genetics shape our personality and life outcomes more than we thought

Scientists have identified more than 1200 genetic variants associated with personality traits,...

Scientists uncover how cancer cells hide from immune system

By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Content from other channels on our network

The Fair Work Ombudsman finds 13 out of 22 aged care providers non-compliant

"Bed block is accelerating and is far beyond sustainable," NSW Minister for Health says

Eureka Prize-winning discovery affects one in four women worldwide

Medicare Mental Health Check In — helping clinicians close the gap

Health professionals FAQ for Medicare Mental Health Check In

Beyond compliance: why ESG in construction is becoming a people issue

Environmental site restoration to transform sewage treatment plant

Organics processing facility opens in Hamilton

Container Exchange appoints new CEO

Floating wetland pods cut greenhouse gas emissions

Critical industries need to know how to isolate, rather than ignore

Guide to assessing low‍-‍emissions thermal energy storage released

WA invests in local wind generator repair and refurbishment

UTS pilot project to mitigate methane emissions

Partners to bring Aussie batteries to global defence and security market